Regulatory Role of Mesenchymal Stem Cells on Secondary Inflammation in Spinal Cord Injury

Qi-Ming Pang,Si-Yu Chen,Sheng-Ping Fu,Hui Zhou,Qian Zhang,Jun Ao,Xiao-Ping Luo,Tao Zhang

DOI: https://doi.org/10.2147/jir.s349572

IF: 4.5

2022-01-26

Journal of Inflammation Research

Abstract:Qi-Ming Pang, 1, 2 Si-Yu Chen, 1 Sheng-Ping Fu, 1, 2 Hui Zhou, 3 Qian Zhang, 4 Jun Ao, 2 Xiao-Ping Luo, 1 Tao Zhang 1, 2 1 Key Laboratory of Cell Engineering of Guizhou Province and Regenerative Medicine Centre, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China; 2 Department of Orthopedics, Affiliated Hospital of Zunyi Medical University, Zunyi, People's Republic of China; 3 The First School of Clinical Medicine, Zunyi Medical University, Zunyi, People's Republic of China; 4 Department of Human Anatomy, Zunyi Medical University, Zunyi, People's Republic of China Correspondence: Tao Zhang; Qian Zhang, Email ; Spinal cord injury (SCI) is a catastrophic condition with high morbidity and mortality that still lacks effective therapeutic strategies. It is well known that the most important stage in SCI pathogenesis is secondary injury, and among the involved mechanisms, the inflammatory cascade is the main contributor and directly influences neurological function recovery. In recent years, increasing evidence has shown that mesenchymal stem cells (MSCs) transplantation is a promising immunomodulatory strategy. Transplanted MSCs can regulate macrophage-, astrocyte-, and T lymphocyte-mediated neuroinflammation and help create a microenvironment that facilitates tissue repair and regeneration. This review focuses on the effects of different types of immune cells and MSCs, specifically the immunoregulatory capacity of MSCs in SCI and repair. We will also discuss how to exploit MSCs transplantation to regulate immune cells and develop novel therapeutic strategies for SCI. Keywords: spinal cord injury, mesenchymal stem cells, immune cells, neuroinflammation, immunoregulation, macrophage, astrocyte, T cell Spinal cord injury (SCI) is a potentially devastating event in the central nervous system (CNS) that can lead to the loss of sensory and motor functions below the damaged segment with huge burdens on patients, their families, and society due to the high treatment cost. 1,2 The global rate of traumatic SCI ranges from 250,000 to 500,000 people annually and will gradually climb with the growing number of people using modern transportation along with aging populations. 3,4 SCI triggers a sequential set of pathophysiological processes that can be classified as primary and secondary injury. 5 Acute primary injury commonly occurs due to the mechanical insult, which can be caused by laceration, contusion, compression, or transection. 6,7 These events severely disrupt neuronal pathways and axonal networks, cause hemorrhage, and compromise the blood-spinal cord barrier (BSCB). 8,9 It is widely believed that the most important phase is secondary injury, which develops a few minutes after the initial injury. It consists of a series of auto-destructive cellular and molecular changes, such as inflammatory response, glial scar formation, edema, thrombosis, free radical release, and apoptotic and necrotic cells death. 10,11 Among the mechanisms of secondary injury, a robust and chronic inflammatory response has been observed at the injury epicenter and in surrounding areas. 12,13 Studies have demonstrated that this response can contribute to a wide range of inflammatory and autoimmune disorders that exacerbate lesion progression and hamper neurological function recovery. 13,14 Unfortunately, there is still a lack of therapeutic methods targeting neuroinflammation; only methylprednisolone has shown efficacy and was approved by the US Food and Drug Administration for clinical treatment. 15,16 However, its use has gradually declined over the past few decades due to the serious complications related to glucocorticoid therapy, such as gastrointestinal bleeding, wound infection, pulmonary embolism, and sepsis. 17,18 Despite the controversies concerning the glucocorticoid treatment, its effects suggest that suppressing the inflammatory response after injury is a viable approach to improve the condition of SCI patients. 19,20 It is therefore imperative to investigate the roles of different types of immune cells on excessive neuroinflammation in order to develop new therapeutic strategies targeting neuroinflammation in the setting of SCI. Figure 1 Schematic depicting the activation and migration of resident and peripheral immune cells following SCI. After primary injury, resident astrocytes, microglia, and other glial cells are immediately activated and migrate to the injury site (top). Subsequently, peripheral inflammatory cells including neutrophils, bone marrow-derived macrophages, and lymphocytes infiltrate into the epicente -Abstract Truncated-

immunology